At @ clinical sites , we randomly assigned @ adults ( mean age , @ years ) with diabetic macular edema involving the macular center to receive intravitreous aflibercept at a dose of @ mg ( @ participants ) , bevacizumab at a dose of @ mg ( @ participants ) , or ranibizumab at a dose of @ mg ( @ participants ) .